In the SFMCs of RA patients, the Exo-srIκB treatment showed a trend of decreasing the frequency of IL-17A-producing cells, and it significantly lowered the frequency of GM-CSF-producing cells compared to the Exo-Naïve treatment (Fig. 3B). This evidence concerns the gene IL17A and rheumatoid arthritis.